Gilead Sciences, Inc.
NEWS
Biotech and pharma companies came roaring out of the gate on the first day of the annual J.P. Morgan Healthcare Conference with big deals, expansions and promises of growth and pipeline sustainability.
Gilead Sciences is acquiring the global rights to develop and commercialize novel small molecules against two targets from Yuhan Corporation, based in South Korea. They drugs will be developed to treat advanced fibrosis related to nonalcoholic steatohepatitis (NASH).
The JP Morgan Healthcare Conference, being held from January 7 through 10 at the Westin St. Francis Hotel in San Francisco, is one of the premier, possible the premier, conferences for the biopharmaceutical industry.
Gilead Sciences, in two days, inked two collaboration deals with two different companies that could pay out an aggregate of more than $3.125 billion. One of those deals is in the area of immuno-oncology, the other in fibrosis.
With the holiday upon us, many companies in the pharma and biotech industry have made some important announcements – some big, some small. BioSpace has gathered a number of announcements that might have gone unnoticed and put them together below.
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
With the year closing out, biotech and pharma companies are making adjustments to their leadership ranks and boards of directors.
With the closure of another year just weeks ahead, this time of year is one that many people use to take a look behind and see what lessons were learned over the past 12 months. For the world of biopharma, it’s also important to see what lessons have been learned.
Gilead Sciences officially announced that long-time Roche veteran, Daniel O’Day, will assume the helm of the company as chairman and chief executive officer beginning March 1. O’Day takes over for John Milligan, who announced his plans to retire by the end of the year in July.
JOBS
IN THE PRESS